B
Benny Vittrup Jensen
Researcher at Gentofte Hospital
Publications - 93
Citations - 4682
Benny Vittrup Jensen is an academic researcher from Gentofte Hospital. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 28, co-authored 85 publications receiving 3293 citations. Previous affiliations of Benny Vittrup Jensen include University of Copenhagen & Herlev Hospital.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
TL;DR: In this paper, a prospective, blinded observational study 120 patients with advanced breast cancer were followed before, during, and a median 3 years after treatment with epirubicin and they had 604 serial radionuclide measurements of left ventricular ejection fraction (LVEF).
Journal ArticleDOI
Serum YKL-40, a new prognostic biomarker in cancer patients?
TL;DR: Retrospective clinical studies of patients with eight different types of primary or advanced solid tumors suggest that serum concentration of YKL-40 may be a new biomarker in cancer patients used as a “prognosticator.”
Journal ArticleDOI
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
TL;DR: A significantly increasing risk of CHF in patients who receive cumulative doses greater than 950 mg/m2 was established, which indicates an additive cardiotoxic effect of irradiation and epirubicin.
Journal Article
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
TL;DR: High serum HER2 and YKL-40 independently identified subgroups of patients with metastatic breast cancer with a poor prognosis that were connected to response to therapy, metastatic pattern, time to progression, and overall survival.